# Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

> **NCT03761901** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 141 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** 1L treatment
- **DRUG:** 2L Treatment
- **DRUG:** 3L treatment

## Key facts

- **NCT ID:** NCT03761901
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-21
- **Primary completion:** 2019-06-19
- **Final completion:** 2019-06-19
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2020-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761901, "Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03761901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*